PDCD1 and glioblastoma: While immunotherapy, particularly agents targeting programmed cell death protein-1 (PD-1)/ programmed death-ligand-1 (PD-L1), has achieved unprecedented success in malignancies such as melanoma [7] and non-small cell lung cancer [8], its efficacy in GBM remains limited [9].